VC
IOBT

Vivo Capital’s IO Biotech IOBT Stock Holding History

Vivo Capital’s Portfolio IOBT Stock Details IOBT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-6,173,439
Closed -$8.58M – 50
2025
Q2 		$8.58M Hold
6,173,439
– – 0.88% 24
2025
Q1 		$6.73M Hold
6,173,439
– – 0.89% 25
2024
Q4 		$5.68M Hold
6,173,439
– – 0.64% 31
2024
Q3 		$6.48M Hold
6,173,439
– – 0.54% 29
2024
Q2 		$7.22M Hold
6,173,439
– – 0.67% 28
2024
Q1 		$10.7M Hold
6,173,439
– – 0.84% 27
2023
Q4 		$11.6M Hold
6,173,439
– – 0.95% 21
2023
Q3 		$8.7M Buy
6,173,439
+3,157,894
+105% +$5.55M 0.95% 26
2023
Q2 		$5.9M Hold
3,015,545
– – 0.41% 34
2023
Q1 		$5.65M Hold
3,015,545
– – 0.39% 32
2022
Q4 		$6.94M Hold
3,015,545
– – 0.8% 26
2022
Q3 		$8.17M Hold
3,015,545
– – 0.9% 30
2022
Q2 		$14.1M Hold
3,015,545
– – 1.41% 17
2022
Q1 		$16M Hold
3,015,545
– – 1.1% 20
2021
Q4 		$19.3M Buy
+3,015,545
New +$29.1M 1.16% 20

Other funds holding IOBT

NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return

Vivo Capital's IOBT Position: Q3 2025 in Review

Vivo Capital sold out of IO Biotech (IOBT) in Q3 2025, closing a stake of 6,173,439 shares — an estimated $8.58M sold.

Vivo Capital first reported a position in IOBT in Q4 2021 and held it in 15 quarters. The position peaked at $19.3M in Q4 2021. 21 funds tracked by Wall St. Rank hold IOBT as of Q3 2025.

  • Vivo Capital reported no remaining IO Biotech position as of Q3 2025 after selling out during the quarter.
  • Vivo Capital sold 6,173,439 IO Biotech shares in Q3 2025, an estimated $8.58M.
  • Vivo Capital first reported a position in IO Biotech in Q4 2021 and held it in 15 quarters.
  • Vivo Capital's IO Biotech position peaked at $19.3M in Q4 2021.
  • 21 funds tracked by Wall St. Rank held IO Biotech as of Q3 2025.

Based on Vivo Capital's 13F filing for Q3 2025, filed 14 Nov 2025.